ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.662,32
-0,56%
S&P 500
5.308,13
0,09%
Dow Jones
39.806,77
-0,49%
Euro vs US Dollar
1,08722
0,11%
Bitcoin
70.958,52
-0,69%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Lyra Therapeutics Inc (LYRA)

  7. Lyra Therapeutics Inc (LYRA) News

LYRA

Lyra Therapeutics (LYRA)

Lyra Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:LYRA
DatumZeitQuelleÜberschriftSymbolFirma
06/05/202413h59GlobeNewswire Inc.Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic RhinosinusitisNASDAQ:LYRALyra Therapeutics Inc
30/04/202422h04GlobeNewswire Inc.Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
26/04/202422h51GlobeNewswire Inc.Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:LYRALyra Therapeutics Inc
21/03/202421h01GlobeNewswire Inc.Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
01/03/202422h01GlobeNewswire Inc.Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:LYRALyra Therapeutics Inc
15/02/202415h18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LYRALyra Therapeutics Inc
15/02/202402h35Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LYRALyra Therapeutics Inc
15/02/202400h18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LYRALyra Therapeutics Inc
14/02/202422h51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LYRALyra Therapeutics Inc
14/02/202422h18Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LYRALyra Therapeutics Inc
13/02/202422h34Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LYRALyra Therapeutics Inc
01/02/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYRALyra Therapeutics Inc
01/02/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYRALyra Therapeutics Inc
08/01/202412h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
28/12/202312h40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
18/12/202322h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
16/11/202323h00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LYRALyra Therapeutics Inc
13/11/202323h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LYRALyra Therapeutics Inc
07/11/202322h23Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LYRALyra Therapeutics Inc
07/11/202322h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
07/11/202322h01GlobeNewswire Inc.Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:LYRALyra Therapeutics Inc
07/11/202313h00GlobeNewswire Inc.Lyra Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:LYRALyra Therapeutics Inc
16/10/202313h00GlobeNewswire Inc.Lyra Therapeutics Announces Appointment of Ronan O’Brien as Chief Legal OfficerNASDAQ:LYRALyra Therapeutics Inc
12/09/202322h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
12/09/202313h00GlobeNewswire Inc.Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus SurgeryNASDAQ:LYRALyra Therapeutics Inc
06/09/202314h00GlobeNewswire Inc.Lyra Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:LYRALyra Therapeutics Inc
01/09/202322h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LYRALyra Therapeutics Inc
01/09/202322h01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LYRALyra Therapeutics Inc
29/08/202313h00GlobeNewswire Inc.Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic RhinosinusitisNASDAQ:LYRALyra Therapeutics Inc
25/08/202322h15Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LYRALyra Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:LYRA

Kürzlich von Ihnen besucht

TG
D7G
Nel ASA
USOTC
ADDYY
Adidas (QX)
NYSE
KO
Coca Cola
USOTC
RHHBY
Roche (QX)
FX
EURGBP
Euro vs Sterling
TG
LHA
Deutsche Lufthansa
CCOM
US30
US 30
USOTC
DTEGY
Deutsche Telekom (QX)
TG
MBG
MercedesBenz
TG
ALV
Allianz
DBI
SDXP
SDAX
TG
NOV
Novo Nordisk
AMEX
XLV
Health Care Select Sector
TG
TUI1
Tui
TG
BAYN
Bayer
TG
432
Arbor Metals
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten